Australia's largest stock trading and investment forum Australia's #1 stock forum

PAR

6.98%

20.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-703

First 703 Last

Share
Profile

Follow
Georgesriver10

1,196 Posts.

53

27/05/20

19:24

Post #: 44876602
Share

Originally posted by Denial: ↑

Old world business value plays are currently seen as being as cheap as they ever been in comparison to growth stories. For good reason they're only likely to become cheaper.

CSL is mature and much loved growth story but still trades on a multiple of 40, which despite it now decades of success is unlikely to live up to these embedded expectations given its current market cap. Nasdaq 100 (qqq) also shows the "paradigm shift" in markets thinking awarding the collective of new world growth companies with a PE of x27 and price to sales ratio x4.

Smaller companies like PAR naturally have a longer runway to grow than larger companies noted above and if we do get classified as a glamour stock then I tend to think our biggest issue will soon become managing PR and the Board's own high expectations and not to sell us short. A triple digit PE in years 1-3 is not unrealistic for glamour stocks with such an non-cyclical addressable market. Thinking about the potential here puts me at least at $10 price target on TGA approval and possible $30 by end of 2021 (assuming approval comes in mid 2021).

Expand

Surely these price targets are far fetched seriously,tell me I'm wrong

PAR Price at posting: $2.68 Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 3,726 more messages in this thread...

First 703 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change -0.015(6.98%)		Mkt cap ! $70.04M

Open	High	Low	Value	Volume
21.0¢	21.0¢	20.0¢	$201.6K	994.6K

Buyers (Bids)

No.	Vol.	Price($)
15	429247	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	13806	2

View Market Depth

No.	Vol.	Price($)
12	389247	0.200
8	133607	0.195
17	238789	0.190
4	92160	0.185
8	122773	0.180

Price($)	Vol.	No.
0.210	13806	2
0.215	28509	1
0.220	59615	6
0.225	28604	2
0.230	16334	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PAR (ASX) Chart

research reports and media, page-703

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

research reports and media, page-703

Top Stories

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News